CompanyPrivateHong Kong

Sino Biopharmaceutical

ClinicalTrials.gov

6-KSep 28Latest SEC filing

Sep 11Latest story

September 2026

Trial tests Tislelizumab plus Anlotinib as consolidation therapy in limited-stage SCLC

Sep 11Trial updateBeiGene Sino Biopharmaceutical